bebtelovimab
Selected indexed studies
- Bebtelovimab. (, 2006) [PMID:35230755]
- Bebtelovimab in the Real World: Promise and Fulfillment. (J Infect Dis, 2022) [PMID:36124710]
- SARS-CoV-2 neutralizing antibody bebtelovimab - a systematic scoping review and meta-analysis. (Front Immunol, 2023) [PMID:37701439]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Bebtelovimab. (2006) pubmed
- Bebtelovimab in the Real World: Promise and Fulfillment. (2022) pubmed
- SARS-CoV-2 neutralizing antibody bebtelovimab - a systematic scoping review and meta-analysis. (2023) pubmed
- LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. (2022) pubmed
- The effect of bebtelovimab on clinical outcomes in patients with COVID-19: A meta-analysis. (2023) pubmed
- LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. (2022) pubmed
- Concerns on Bebtelovimab (LY-CoV1404) used to neutralize Omicron subvariants. (2023) pubmed
- An EUA for bebtelovimab for treatment of COVID-19. (2022) pubmed
- Bebtelovimab for High-Risk Outpatients With Early COVID-19 in a Large US Health System. (2022) pubmed
- Clinical outcomes and frequency of persistent infection among immunosuppressed patients treated with bebtelovimab for COVID-19 infection at an ambulatory cancer center. (2024) pubmed